Antiviral activity of cyclopentenyl nucleosides against orthopox viruses (smallpox, monkeypox and cowpox)

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 1, 2003, Pages 9-12

  Chu, C K ^a   Jin, Y H ^a   Baker, R O ^b   Huggins, J ^b  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 FLUOROCYTOSINE 15; ADENINE 2; ADENINE DERIVATIVE; ANTIVIRUS AGENT; CARBOCYCLIC NUCLEOSIDE; CYTOSINE 14; CYTOSINE DERIVATIVE; DEXTRO CYCLOPENTENYLNUCLEOSIDE; KETONE DERIVATIVE; LEVO CYCLOPENT 2 ENONE 13; NEPLANOCIN A; RIBOSE; UNCLASSIFIED DRUG; ADENOSINE; CYCLOPENTENYL CYTOSINE; CYTIDINE; DRUG DERIVATIVE; NUCLEOSIDE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CERCOPITHECIDAE; COWPOX VIRUS; CYTOTOXICITY; DRUG SYNTHESIS; NONHUMAN; ORTHOPOXVIRUS; POXVIRUS; RING CLOSING METATHESIS; SMALLPOX VIRUS; VACCINIA VIRUS; ANIMAL; CELL LINE; CELL SURVIVAL; DRUG EFFECT; MONKEYPOX VIRUS; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ORTHOPOX VIRUS; VARIOLA VIRUS;

ADENOSINE; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CELL SURVIVAL; COWPOX VIRUS; CYTIDINE; MONKEYPOX VIRUS; NUCLEOSIDES; ORTHOPOXVIRUS; STRUCTURE-ACTIVITY RELATIONSHIP; VARIOLA VIRUS;

EID: 0037421038     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00841-7     Document Type: Article

References (28)

1. Kusaka T., Yamamoto H., Muroi M., Kishi T., Mizuno K. J. Antibiot. 21:1968;255.
2. Yaginuma S., Muto N., Tsujino M., Sudate Y., Hatashi M., Otani M. J. Antibiot. 34:1981;359.
3. (a) Daluge S.M., Good S.S., Faletto M.B., Miller W.H., St. Clair M.H., Boone L.R., Tisdale M., Parry N.R., Reardon J.E., Dornsife R.E., Averett D.R., Krenitsky T.A. Antimicrob. Agents Chemother. 41:1997;1082
4. (b) Weller S., Radomski K.M., Lou Y., Stein D.S. Antimicrob. Agents Chemother. 44:2000;2052.
5. Vince R., Hua M. J. Med. Chem. 33:1990;17.
6. Bennett L.L. Jr., Brockman R.W., Rose L.M., Allan P.W., Shaddix S.F., Clayton J.D. Mol. Pharmacol. 27:1985;666.
7. Wolfe M.S., Borchardt R.T. J. Med. Chem. 34:1991;1521.
8. De Clercq E. Antimicrob. Agents Chemother. 28:1985;84.
9. Shuto S., Obara T., Saito Y., Andrei G., Snoeck R., De Clercq E., Matsuda J. Med. Chem. 39:1996;2392.
10. (a) Shuto S., Minakawa N., Niizuma S., Kim H.S., Wataya Y., Matsuda A. J. Med. Chem. 45:2002;748
11. (b) Ono M., Nishimura K., Tsubouchi H., Nagaoka Y., Tomioka K. J. Org. Chem. 66:2001;8199.
12. (a) Song G.Y., Paul V., Choo H., Morrey J., Sidwell R.W., Schinazi R.F., Chu C.K. J. Med. Chem. 44:2001;3958
13. (b) Song G.Y., Naguib F.N., El Kouni M.H., Chu C.K. Nucleosides Nucleotides Nucleic Acid. 20:2001;1915
14. (c) Wang P., Gullen B., Newton M.G., Cheng Y.C., Schinazi R.F., Chu C.K. J. Med. Chem. 42:1999;3390.
15. (a) Wolfe M.S., Borcherding D.R., Borchardt R.T. Tetrahedron Lett. 30:1989;1453 (b) Borcherding D.R., Scholtz S.A., Borchardt R.T. J. Org. Chem. 52:1987;5457 (c) Ali S.M., Ramesh K., Borchardt R.T. Tetrahedron Lett. 31:1990;1509.
16. (a) Wolfe M.S., Borcherding D.R., Borchardt R.T. Tetrahedron Lett. 30:1989;1453 (b) Borcherding D.R., Scholtz S.A., Borchardt R.T. J. Org. Chem. 52:1987;5457 (c) Ali S.M., Ramesh K., Borchardt R.T. Tetrahedron Lett. 31:1990;1509.
17. (a) Wolfe M.S., Borcherding D.R., Borchardt R.T. Tetrahedron Lett. 30:1989;1453 (b) Borcherding D.R., Scholtz S.A., Borchardt R.T. J. Org. Chem. 52:1987;5457 (c) Ali S.M., Ramesh K., Borchardt R.T. Tetrahedron Lett. 31:1990;1509.
18. (a) Jin Y.H., Chu C.K. Tetrahedron Lett. 43:2002;4141
19. (b) Similar strategies using RCM reaction have been published in Seepersaud M., Al-Abed Y. Tetrahedron Lett. 41:2000;7801
20. (c) Choi W.J., Park J.G., Yoo S.J., Kim H.O., Moon H.R., Chun M.W., Jung Y.H., Jeong L.S. J. Org. Chem. 61:2001;6490
21. (d) Lee K., Cass C., Jacobson K.A. Org. Lett. 3:2001;597.
22. Davis, B. D.; Dulbecco, R.; Eisen, H. N.; Ginsberg, H. S.; Wood, W. G. Jr.; McCarty, M. In Microbiology, 2nd ed.; Harper & Row: Hagerstown, MD, 1973; p 1258.
23. Klietmann W.F., Ruoff K.L. Clin. Micro. Rev. 14:2001;364.
24. De Clercq E. Clin. Micro. Review. 14:2001;382.
25. (a) Henderson D.A. Emerg. Infect. Dis. 5:1999;537
26. (b) Steven R.R., Michael M., Cynthia K., Karen L.G. Emerg. Infect. Dis. 7:2001;920.
27. 4Si: C, 59.56; H, 10.00. Found: C, 60.17; H, 9.60.
28. 4), pH 3.5). Plates were rocked for 30 min at 150 RPM, and the optical density (OD) of the wells at a wavelength of 450 nm was measured on a plate reader. The data were graphed and analyzed by using the four parameter-log it curve fit option of a curve-fitting program (Molecular Devices, Menlo Park, CA, USA) to determine the 50% inhibitory and cytotoxic drug concentration.